Use of recombinant interleukin-2 in traumatic disease in veterinary medicine

Тhe article presents analysis of current information on the possibility of using recombinant interleukin-2 in traumatic disease in veterinary medicine. The analysis included publications from the following databases - P ubMed, MedLine, BIOSIS, ToxiNet, CANCERLIT, CINAHL, CISCOM, EMBASE, International Pharmaceutical Abstracts, and NAPRALERT, using 10 keywords and their combinations. It was shown that in trauma of any genesis, an immunodeficiency state occurs associated with an imbalance of Th1/Th2 cytokines. The use of recombinant interleukin-2 restores synthesis of endogenous interleukin-2, provides adequate targeted drug correction of immune dysfunctions, increasing the clinical and immunological effectiveness of therapeutic measures.